Specifications molecular diagnostics for MDS and MPN
The MDS/MPN Panel (IAD160996_182) exists of 186 amplicons and is covering 100% of submitted areas (all coding regions (exons)) and is able to analyze variants in 21 genes implicated in MDS/MPN.
Download specifications as pdf
Design MDS/MPN Panel
Indicated exons (Table 1) include flanking intronic regions based on 5 base exon padding. For some genes the 5 base exon padding is not achieved or only a hotspot location is covered. See table 2 for detailed coverage information.
Table 1. Design MDS/MPN panel
Gene |
Chromosome |
NCBI Transcript |
Exon |
Coverage % |
ASXL1 |
Chr20 |
NM_015338.5 |
13 |
100 |
BCOR |
ChrX |
NM_001123385.1 |
2-15 (full) |
100 |
CALR |
Chr19 |
NM_004343.3 |
8, 9 |
100 |
CBL |
Chr11 |
NM_005188.3 |
8, 9 |
100 |
CSF3R |
Chr1 |
NM_156039.3 |
12-17 |
100 |
ETNK1 |
Chr12 |
NM_018638.4 |
3 |
100 |
ETV6 |
Chr12 |
NM_001987.4 |
3-8 (full) |
100 |
EZH2 |
Chr7 |
NM_004456.4 |
2-20 (full) |
100 |
IDH1 |
Chr2 |
NM_005896.3 |
4 |
100 |
IDH2 |
Chr15 |
NM_002168.3 |
4 |
100 |
JAK2 |
Chr9 |
NM_004972.3 |
12, 14 |
100 |
KRAS |
Chr12 |
NM_033360.3 |
2, 3 |
100 |
MPL |
Chr1 |
NM_005373.2 |
4, 10, 12 |
100 |
NRAS |
Chr1 |
NM_002524.4 |
2, 3 |
100 |
SETBP1 |
Chr18 |
NM_015559.2 |
4 |
100 |
SF3B1 |
Chr2 |
NM_012433.3 |
12-16 |
100 |
SRSF2 |
Chr17 |
NM_003016.4 |
1 |
100 |
STAG2 |
ChrX |
NM_001042749.2 |
3-35 (full) |
100 |
TP53 |
Chr17 |
NM_000546.5 |
2-11 |
100 |
TP53β |
Chr17 |
NM_001126114.2 |
alt 10 |
100 |
TP53γ |
Chr17 |
NM_001126113.2 |
Alt 10 |
100 |
U2AF1 |
Chr21 |
NM_006758.2 |
2, 6 |
100 |
ZRSR2 |
ChrX |
NM_005089.3 |
1-11 (full) |
100 |
Table 2. Aberrant covered regions MDS/MPN panel
Gene |
Exon |
Coding region |
KRAS |
3 |
c.112-1 - c.290+5 |
MPL |
1 |
c.539 - c.690+5 |
MPL |
12 |
c.1677 - c.1871 |
SETBP1 |
4 |
c.2302 - c.2753 |
SF3B1 |
12 |
c.1540-1 - c.1719+5 |
SF3B1 |
14 |
c.1807-3 - c.2077+5 |
SF3B1 |
15 |
c.2078-1 - c.2223+5 |
TP53 |
2 |
c.-5 - c.74+2 |
TP53 |
3 |
c.75-5 - c.96+2 |
Coverage of the NGS MDS/MPN Panel
Coverage is the number of times a base is sequenced. The deeper the coverage of each base the greater the reliability and sensitivity of the sequencing assay. The minimum depth of coverage required for detection of somatic variants with the MDS/MPN Panel is 500X. The percentage of Target Base coverage (%Base500x) is the percentage of target bases in a panel that is covered at least 500 times.
Coverage for the NGS MDS/MPN panel is in silico validated and is 100% for all amplicons representing 21 different genes. The percentage of target bases that is covered at least 500 times (%Base500x) is at least 99.04% at 2.000.000 Mapped Reads. With this acceptance criteria two amplicons failed to yield >500 times coverage, specific locations are listed in Table 3. One amplicon in BCOR results in a too low coverage of 197bp at the 5’side of exon 4. Besides BCOR, one amplicon in MPL has less than 500x coverage. This amplicon is covering the coding region of exon 10 and 5 base flanking intronic regions on both sides (total 106bp). There are several MDS/MPN related variants described in both regions.
Table 3. Information failed amplicons MDS/MPN panel
|
GRCh37/hg19 coordinates |
|
Bases failing |
|
|
|
Chr. |
Start |
End |
Gene |
coverage 500X |
Exon |
Missing COSMIC |
ChrX |
39933684 |
39933486 |
BCOR |
197 |
4 |
Several |
Chr1 |
43814929 |
43815035 |
MPL |
106 |
10 |
Several |
Reporting: addition hematological malignancies variants
This test does not distinguish between somatic and germ line alterations in analyzed gene regions, particularly when variant allele frequencies (VAF) are near 50% or 100%. If nucleotide alterations in genes associated with germ line mutation syndromes are present and there is also a strong clinical suspicion or family history of malignant disease predisposition, appropriate genetic counselling may be indicated.
Variants detected between 5% and 10% Variant Allele Frequency may indicate subclonal tumor populations. However the clinical significance of these findings may not always be distinct. It is demonstrated that in blood DNA samples from individuals with advancing age and who do not have a hematologic neoplasm, a low incidence of gene variants that are associated with myeloid neoplasms can be detected. This phenomenon of clonal hematopoiesis of indeterminate potential (CHIP) may not be clearly distinguishable from tumor-associated mutations, especially if detected as a sole abnormality (Steensma et al).
Correlation with clinical, histopathologic and additional laboratory findings is required for final interpretation of the results. The final interpretation of results for clinical management of the patient is the responsibility of the managing physician.